Related Experiment Video

Updated: Jun 25, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

Vanessa Milano1, Yuji Piao, Tiffany LaFortune

  • 1Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Molecular Cancer Therapeutics
|February 5, 2009
PubMed

Insights

Dasatinib, a tyrosine kinase inhibitor, effectively reduces glioblastoma cell invasion and promotes autophagic cell death. Combination therapy with dasatinib and temozolomide shows enhanced efficacy for treating this aggressive brain tumor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioblastoma is a highly invasive brain tumor characterized by rapid growth.
  • Dasatinib (BMS-354825) is a small-molecule inhibitor targeting tyrosine kinases implicated in cancer.
  • Understanding dasatinib's mechanism in glioblastoma could reveal new therapeutic strategies.

Purpose of the Study:

  • To investigate the effects of dasatinib on human glioblastoma cells.
  • To evaluate dasatinib's impact on glioblastoma cell invasion and death pathways.
  • To assess the efficacy of combining dasatinib with standard chemotherapy agents.

Main Methods:

  • Treatment of glioblastoma cell lines with dasatinib at low nanomolar concentrations.
  • Analysis of signaling pathways including phospho-SRC, AKT, and ribosomal protein S6.
  • Assessment of invasive potential, cell cycle, and cell death via acridine orange and Western blotting for light chain 3.
  • Combination studies with dasatinib and temozolomide, carboplatin, or irinotecan.

Main Results:

  • Dasatinib decreased key signaling proteins (phospho-SRC, AKT, S6) in glioblastoma cells.
  • Glioma cells with functional PTEN showed increased sensitivity to dasatinib.
  • In vitro invasion was reduced, with disrupted focal adhesions and decreased focal adhesion kinase activity.
  • Dasatinib induced significant autophagic cell death, not G1 cell cycle arrest.
  • Combination of dasatinib and temozolomide synergistically increased cell death and cell cycle disruption.

Conclusions:

  • Dasatinib effectively inhibits glioblastoma cell signaling and invasion.
  • Dasatinib induces autophagic cell death in glioblastoma cells.
  • Combination therapy with dasatinib and temozolomide demonstrates significant therapeutic potential for glioblastoma treatment.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...